Olaparib - CAS 763113-22-0
Catalog number: 763113-22-0
Category: Inhibitor
Not Intended for Therapeutic Use. For research use only.
COA:
Inquire
Targets:
PARP
Description:
Olaparib, also known as AZD-2281 or KU-59436, is a small molecule inhibitor of the nuclear enzyme poly(ADP-ribose) polymerase (PARP) with potential chemosensitizing, radiosensitizing, and antineoplastic activities. Olaparib selectively binds to and inhibits PARP, inhibiting PARP-mediated repair of single strand DNA breaks; PARP inhibition may enhance the cytotoxicity of DNA-damaging agents and may reverse tumor cell chemoresistance and radioresistance. PARP catalyzes post-translational ADP-ribosylation of nuclear proteins and can be activated by single-stranded DNA breaks.
Publictions citing BOC Sciences Products
  • >> More
Purity:
>98%
Appearance:
white solid powder
Synonyms:
KU-59436, KU-0059436. AZD2281; AZD=2281; AZD 2281;
MSDS:
Inquire
1.Synthesis of Olaparib Derivatives and Their Antitumor Activities
LOU Xi-yu, YANG Xuan. Chem. Res. Chin. Univ. 2013, 29(2), 231—235
In order to improve its antitumor effects and discover more potent and effective antitumor agents, our group performed chemical modification of Olaparib(modification sites are shown in Fig.1), synthesized a series of Olaparib analogues and evaluated their in vitro antitumor activities against BRCA1-deficient cell lines HCC1937, Capan-1 and MDA-MB-436. We herein report the synthesis of these compounds, and their in vitro antitumor activity. The synthetic routes of the target compounds are outlined in Schemes 1 and 2.
2.A Phase I study of olaparib and irinotecan in patients with colorectal cancer: Canadian Cancer Trials Group IND 187
Eric X. Chen & Derek J. Jonker & Lillian L. Siu. Invest New Drugs (2016) 34:450–457
In preclinical studies, olaparib and other PARP inhibitors were shown to potentiate the anti-tumor effect of topoisomer ase I inhibitors, such as irinotecan, and combining PARP and topoisomerase I inhibitors was considered to be a potential therapeutic strategy. We conducted a phase I study to evaluate the safety and tolerability of olaparib in combination with irinotecan, and to determine the recommended phase II dose (RP2D) of this combination in patients with advanced colorectal cancer (NCT00535353). Secondary objectives included determining olaparib pharmacokinetics with and without irinotecan, irinotecan pharmacokinetics in the presence of olaparib, and collecting preliminary evidence of anti-tumor activity.
3.Evaluation of the pharmacodynamics and pharmacokinetics of the PARP inhibitor olaparib: a Phase I multicentre trial in patients scheduled for elective breast cancer surgery
Nigel Bundred & Janis Gardovskis & Janusz Jaskiewicz. Invest New Drugs (2013) 31:949–958
Tumour exposure to olaparib was achieved in all but one of the post-treatment samples obtained from patients dosed with olaparib 30 mg bid and above; the exception was the tumour sample from one patient in the 200 mg bid dose group. Within the 10 mg bid group, olaparib could not be detected in the post-treatment tumour tissue samples from seven patients, and was less than 100 ng/g in samples from a further two patients (assay LOQ=40 ng/g). As with the plasma measurements, wide inter-patient variability was observed in the olaparib concentrations in tumour tissue samples (Fig. 1c); no clear dose-exposure relationship was evident in these samples.
4.Olaparib: a promising PARP inhibitor in ovarian cancer therapy
Ying Chen • Lei Zhang • Quan Hao. Arch Gynecol Obstet (2013) 288:367–374
However, a comprehensive understanding of the therapeutic applications of Olaparib in tumor cells was not available until recently. Within this review, we briefly summarize the recent research progress on the efficacy and tolerability of Olaparib in OC patients with or without BRCA mutation. Hopefully the information in this article summarizing the recent studies advances will lead to a better understand of the mechanisms of Olaparib in genome stability maintenance and provide valuable clues in the selection of patient populations that will respond to Olaparib.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related PARP Products


CAS 1859053-21-6 Rucaparib Camsylate

Rucaparib Camsylate
(CAS: 1859053-21-6)

Rucaparib camsylate is an inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, which work in DNA repair process. It was approved for the treatment of ovari...

CAS 1419949-20-4 TNKS656

TNKS656
(CAS: 1419949-20-4)

NVP-TNKS656, also known as TNKS656, is a potent and orally active Tankyrase Inhibitor. With an enthalpy-driven thermodynamic signature of binding, highly favor...

CAS 344458-15-7 PJ34

PJ34
(CAS: 344458-15-7)

PJ34 is a novel and potential PARP inhibitor with potential anticancer activity. PJ34 has a high affinity for PARP-1 (IC(50) = 20 nM) .

CAS 1038915-73-9 MK-4827 tosylate

MK-4827 tosylate
(CAS: 1038915-73-9)

MK-4827 tosylate is a selective inhibitor of PARP1/PARP2 with IC50 of 3.8 nM/2.1 nM. It has a great activity in cancer cells with mutant BRCA-1 and BRCA-2, >330...

CAS 664993-53-7 JW55

JW55
(CAS: 664993-53-7)

CAS 1380672-07-0 G007-LK

G007-LK
(CAS: 1380672-07-0)

G007-LK is a potent, "rule of 5" compliant and a metabolically stable TNKS1/2 inhibitor. G007-LK displayed high selectivity toward tankyrases 1 and 2 with bioch...

CAS 1174043-16-3 AZD-2461

AZD-2461
(CAS: 1174043-16-3)

AZD2461 is a novel and potent PARP inhibitor with lower affinity to P-glycoprotein. AZD2641 is currently in Phase I clinical study. The study is being conducted...

CAS 934162-61-5 A-966492

A-966492
(CAS: 934162-61-5)

A-966492 is a novel and potent inhibitor of PARP1 and PARP2 with Ki of 1 nM and 1.5 nM, respectively

CAS 284028-89-3 XAV-939

XAV-939
(CAS: 284028-89-3)

CAS 1207456-00-5 BMN-673 8R,9S

BMN-673 8R,9S
(CAS: 1207456-00-5)

BMN-673 is an orally bioavailable inhibitor of the nuclear enzyme poly(ADP-ribose) polymerase (PARP) with potential antineoplastic activity. PARP inhibitor BMN-...

CAS 328543-09-5 AG-14361

AG-14361
(CAS: 328543-09-5)

AG14361 is a PARP-1 inhibitor with Ki < 5 nmol/L. AG14361 is at least 1000-fold more potent than the benzamides. The IC50 for AG14361 is 29 nM in permeabilized ...

CAS 763113-22-0 Olaparib

Olaparib
(CAS: 763113-22-0)

Olaparib, also known as AZD-2281 or KU-59436, is a small molecule inhibitor of the nuclear enzyme poly(ADP-ribose) polymerase (PARP) with potential chemosensiti...

CAS 912445-05-7 ABT-888

ABT-888
(CAS: 912445-05-7)

CAS 160003-66-7 Iniparib

Iniparib
(CAS: 160003-66-7)

BSI-201 is a small-molecule prodrug inhibitor of the nuclear enzyme poly(ADP-ribose) polymerase-1 (PARP-1) with potential chemosensitizing, radiosensitizing and...

CAS 912444-00-9 Veliparib

Veliparib
(CAS: 912444-00-9)

Veliparib (ABT-888) is a potent inhibitor of PARP1 and PARP2 with Ki of 5.2 nM and 2.9 nM, respectively. In HCT-116 and HT-29 cell lines, the ability of ABT-888...

CAS 1140964-99-3 E7449

E7449
(CAS: 1140964-99-3)

E7449 is an orally bioavailable, potent, small molecule inhibitor of PARP1 and PARP2, which enhances the efficacy of radiotherapy and chemotherapy and has poten...

CAS 1345098-78-3 XMD16-5

XMD16-5
(CAS: 1345098-78-3)

XMD16-5is a novel non-receptor tyrosine kinase TNK2 inhibitor (IC50= 16 nM and 77 nM for D163E and R806Q mutant TNK2, respectively)

Protease-Activated Receptor-2, amide

Protease-Activated Receptor-2, amide, also known as SLIGKV-NH2, is a highly potent protease-activated receptor-2 (PAR2) activating peptide and can also be utliz...

NMS-P118
(CAS: 1262417-51-5)

NMS-P118 is a highly selective Poly(ADP-ribose) Polymerase 1 (PARP-1) inhibitor with excellent ADME, pharmacokinetic profiles and high efficacy in vivo originat...

CAS 283173-50-2 Rucaparib

Rucaparib
(CAS: 283173-50-2)

Rucaparib, also named as AG-014699 or PF-01367338, is a poly (ADP ribose) polymerase (PARP) inhibitor. PARP is a DNA damage-activated nuclear enzyme that has a ...

Chemical Structure

CAS 763113-22-0 Olaparib

Quick Inquiry

Verification code

Featured Items